Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...
Pharmabiz3d
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...
American Association of Individual Investors18d
3 Undervalued Biotechnology Stocks for Monday, February 24
Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...
Medindia23d
Epidural Steroid Injections for Chronic Back Pain: An AAN Systematic Review
MINNEAPOLIS, Feb. 19, 2025 /PRNewswire/ -- The American Academy of Neurology (AAN) has developed a new systematic review to summarize for neurologists and other clinicians the evidence for ...
PharmaTimes24d
Heather Knight
Baxter has appointed Heather Knight as Executive Vice President and COO Baxter International has appointed Heather Knight, who has been leading the company’s Medical Products and Therapies unit, as ...
Medindia25d
CanSinoBIO to Showcase China's Vaccine Innovation at 2025 World Government Summit in Dubai
DUBAI, UAE, Feb. 17, 2025 /PRNewswire/ -- CanSino Biologics Inc. (CanSinoBIO or the Company), a leading Chinese vaccine innovator, has been invited to the 2025 World Government Summit in Dubai ...